Search Results

By Hagop Kantarjian, MD, and Mary Alma Welch, MMSc  / February 10, 2023

Influence of the ‘Mark Cuban Effect’ on Cancer Drug Prices in the United States: Focus on CML

The advent of the BCR::ABL1 tyrosine kinase inhibitors for the treatment of Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) was a therapeutic miracle that changed the management paradigm of CML. The first of them, imatinib, was developed in the late 1990s.1,2 Within a few...